Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Re Depth 15 (also known as RE-Depth 15) is an oral prebiotic and probiotic supplement developed and marketed by Austrak. It is formulated as a capsule containing a combination of beneficial bacterial strains—specifically *Bifidobacterium longum* (5 billion spores), *Lactobacillus acidophilus* (5 billion spores), and *Streptococcus thermophilus* (5 billion spores)—along with the prebiotic fiber fructo-oligosaccharides (FOS) (100 mg). Positioned within Austrak's nephrology portfolio, Re Depth 15 is designed to support the gut-kidney axis by restoring a healthy balance of gut microbiota, which can help mitigate the accumulation of uremic toxins in patients with chronic kidney disease. Additionally, it is utilized to manage gastrointestinal dysbiosis, antibiotic-associated diarrhea, irritable bowel syndrome (IBS), and inflammatory bowel disease (IBD).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Re Depth 15.